
Pfizer Acquires Metsera in $10 Billion Obesity Drug Deal
Novo Nordisk's CEO Mike Doustdar withdrew from a $10 billion bid for Metsera after Pfizer matched its offer, highlighting intense competition in the obesity drug market. Despite setbacks, Novo plans to pursue other acquisitions and focus on its pipeline, including new treatments and potential breakthroughs like a pill form of semaglutide. The company is shifting towards a more aggressive, market-driven approach to regain its leadership in the booming weight-loss industry.

